What are SGLT2 inhibitors?

SGLT2 (sodium-glucose co-transporter 2) inhibitors are prescription oral medications used to treat type 2 diabetes.

What generic and brand names of SGLT2 inhibitors are available in the US?

Brand and generic names of SGLT2 inhibitors and combination products that contain SGLT2 inhibitors include:

  • canagliflozin (Invokana)
  • canagliflozin/metformin (Invokamet)
  • canagliflozin/metformin extended release (Invokamet XR)
  • dapagliflozin (Farxiga)
  • dapagliflozin/metformin extended release (Xigduo XR)
  • dapagliflozin/saxagliptin (Qtern)
  • empagliflozin (Jardiance)
  • empagliflozin/linagliptin (Glyxambi)
  • empagliflozin/metformin (Synjardy)
  • empagliflozin/metformin extended release (Synjardy XR)
  • ertugliflozin (Steglatro)
  • ertugliflozin/metformin (Segluromet)
  • ertugliflozin/sitagliptin (Steglujan)

Do I need a prescription for SGLT2 inhibitors?

Yes

How do SGLT2 inhibitors work?

  • SGLT2 inhibitors reduce blood glucose by blocking the action of a protein called sodium-glucose co-transporter-2 (SGLT2) in the kidney. This protein is responsible for reabsorbing sugar back into the body from urine. Blocking this protein prevents the kidney from reabsorbing glucose from urine and causes glucose to be removed from the body through urine. This lowers the level of glucose in the blood.
  • SGLT2 inhibitors also reduce blood pressure and cause weight loss. In one study, empagliflozin (Jardiance) significantly reduced the risk of death from cardiovascular causes, death from any cause, and the risk of hospitalization for heart failure in people with type 2 diabetes.
  • The FDA approved the first SGLT2 inhibitor, canagliflozin (Invokana), in 2013.

QUESTION

______________ is another term for type 2 diabetes. See Answer

What are the uses for SGLT2 inhibitors?

What are the side effects of SGLT2 inhibitors?

WARNING

On Aug. 29, 2018, the FDA issued a warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called SGLT2 inhibitors. This serious rare infection, called necrotizing fasciitis of the perineum, is also referred to as Fournier’s gangrene.

SGLT2 inhibitors are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine. First approved in 2013, medicines in the SGLT2 inhibitor class include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. In addition, empagliflozin is approved to lower the risk of death from heart attack and stroke in adults with type 2 diabetes and heart disease. Untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease.

Seek medical attention immediately if you experience any symptoms of tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, and have a fever above 100.4 F or a general feeling of being unwell. These symptoms can worsen quickly, so it is important to seek treatment right away.

On May 15, 2015, the FDA informed the public that SGLT2 inhibitors have been associated with increased risk of ketoacidosis in people with diabetes.

Common side effects

The most common side effect of SGLT2 inhibitors include:

Serious side effects of SGLT2 inhibitors include:

SLIDESHOW

Type 2 Diabetes Diagnosis, Treatment, Medication See Slideshow

What are the dosages for SGLT2 inhibitors?

SGLT2 inhibitors are available as tablets.

  • canagliflozin (Invokana): 100, 300 mg tablets
  • dapagliflozin (Farxiga): 5, 10 mg tablets
  • empagliflozin (Jardiance): 10, 25 mg tablets

Which drugs or supplements interact with SGLT2 inhibitors?

  • Combining SGLT2 inhibitors with insulin or drugs that increase insulin secretion increases the risk of hypoglycemia.
  • Combining SGLT2 inhibitors with diuretics increases the frequency of urination and the risk of dehydration.
  • Rifampin, phenytoin, phenobarbital, ritonavir (Norvir) increase the removal of canagliflozin from the body by increasing the action of UDP glucuronosyl transferases (UGT) enzymes. UGT are enzymes that convert chemicals in the body to other types of chemicals that dissolve better in water and are easier to remove from the body. This interaction may reduce the efficacy of canagliflozin. Therefore, the dose of canagliflozin may need to be increased when it is combined with drugs that increase its removal form the body.
  • Canagliflozin increases blood levels and the effect of digoxin.
  • The prescribing information for dapagliflozin does not list any drug interactions.

Are SGLT2 inhibitors safe to take during pregnancy or while breastfeeding?

SGLT2 inhibitors have not been adequately evaluated in pregnant women. SGLT2 inhibitors affected kidney development and maturation in animals.

It is unknown whether SGLT2 inhibitors are secreted in human breast milk. To avoid any risk to the infant, breastfeeding women should stop either SGLT2 treatment or breastfeeding.

Subscribe to MedicineNet's Diabetes Newsletter

By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.

Summary

SGLT2 (sodium-glucose co-transporter 2) inhibitors is a class of drugs prescribed to treat type 2 diabetes in conjunction with diet and exercise. Review side effects, drug interactions, preparations, and pregnancy and breastfeeding safety information prior to taking any medication.

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 7/2/2019
References
Some sections provided courtesy of the U.S. Food and Drug Administration (FDA) prescribing information

U.S. Food and Drug Administration. "FDA approves Invokana to treat type 2 diabetes First in a new class of diabetes drugs."
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm>

U.S. Food and Drug Administration. "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes."
<https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes>

Zinman, B. et al. "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM." New England Journal of Medicine. N.p., 17 Sept. 2015. Web. 27 Apr. 2016.
CONTINUE SCROLLING FOR RELATED SLIDESHOW